Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ECOR NYSE:INFU NASDAQ:KRMD NASDAQ:LUCD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECORelectroCore$6.40+5.4%$7.90$4.16▼$10.49$50.36M0.8885,496 shs78,216 shsINFUInfuSystem$9.15+2.3%$9.29$5.43▼$11.04$184.67M1.4169,051 shs150,542 shsKRMDKORU Medical Systems$4.03-0.7%$4.12$3.20▼$6.61$186.49M0.41139,807 shs202,715 shsLUCDLucid Diagnostics$0.97-0.3%$1.02$0.90▼$1.63$196.83M1.071.90 million shs1.24 million shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECORelectroCore+3.23%-6.90%-27.95%-2.10%-16.51%INFUInfuSystem+0.22%-3.87%-5.10%-13.20%+63.14%KRMDKORU Medical Systems-1.22%-4.02%+4.10%+1.00%+20.47%LUCDLucid Diagnostics+2.01%-2.20%-8.99%-24.27%-13.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECORelectroCore$6.40+5.4%$7.90$4.16▼$10.49$50.36M0.8885,496 shs78,216 shsINFUInfuSystem$9.15+2.3%$9.29$5.43▼$11.04$184.67M1.4169,051 shs150,542 shsKRMDKORU Medical Systems$4.03-0.7%$4.12$3.20▼$6.61$186.49M0.41139,807 shs202,715 shsLUCDLucid Diagnostics$0.97-0.3%$1.02$0.90▼$1.63$196.83M1.071.90 million shs1.24 million shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECORelectroCore+3.23%-6.90%-27.95%-2.10%-16.51%INFUInfuSystem+0.22%-3.87%-5.10%-13.20%+63.14%KRMDKORU Medical Systems-1.22%-4.02%+4.10%+1.00%+20.47%LUCDLucid Diagnostics+2.01%-2.20%-8.99%-24.27%-13.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceECORelectroCore 2.00Hold$18.00181.25% UpsideINFUInfuSystem 2.67Moderate Buy$15.0063.93% UpsideKRMDKORU Medical Systems 2.60Moderate Buy$7.2579.90% UpsideLUCDLucid Diagnostics 2.60Moderate Buy$4.19333.17% UpsideCurrent Analyst Ratings BreakdownLatest ECOR, LUCD, KRMD, and INFU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026LUCDLucid Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/15/2026KRMDKORU Medical Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026ECORelectroCore Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026KRMDKORU Medical Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/8/2026LUCDLucid Diagnostics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $9.255/29/2026KRMDKORU Medical Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026LUCDLucid Diagnostics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.005/15/2026LUCDLucid Diagnostics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.505/6/2026LUCDLucid Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026KRMDKORU Medical Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookECORelectroCore$34.90M1.52N/AN/A($0.21) per share-30.48INFUInfuSystem$142.40M1.30$0.72 per share12.79$2.47 per share3.70KRMDKORU Medical Systems$43.26M4.28N/AN/A$0.37 per share10.89LUCDLucid Diagnostics$4.71M41.68N/AN/A($0.31) per share-3.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateECORelectroCore-$13.97M-$1.77N/AN/AN/A-44.08%-1,956.38%-83.30%8/5/2026 (Estimated)INFUInfuSystem$870K$0.38152.5329.52N/A1.12%2.78%1.41%N/AKRMDKORU Medical Systems-$2.64M-$0.05N/A80.60N/A-5.27%-13.61%-8.33%8/5/2026 (Estimated)LUCDLucid Diagnostics-$58.01M-$0.47N/AN/AN/A-876.72%N/A-116.26%8/12/2026 (Estimated)Latest ECOR, LUCD, KRMD, and INFU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026LUCDLucid Diagnostics-$0.04N/AN/AN/A$1.43 millionN/A8/5/2026Q2 2026ECORelectroCore-$0.41N/AN/AN/A$9.49 millionN/A8/5/2026Q2 2026KRMDKORU Medical Systems-$0.02N/AN/AN/A$11.62 millionN/A5/13/2026Q1 2026LUCDLucid Diagnostics-$0.05-$0.07-$0.02-$0.17$1.38 million$1.26 million5/6/2026Q1 2026ECORelectroCore-$0.59-$0.59N/A-$0.59$9.01 million$9.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthECORelectroCoreN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/AKRMDKORU Medical SystemsN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioECORelectroCoreN/A1.020.86INFUInfuSystem0.501.981.59KRMDKORU Medical SystemsN/A2.331.82LUCDLucid DiagnosticsN/A1.071.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipECORelectroCore26.74%INFUInfuSystem71.13%KRMDKORU Medical Systems58.60%LUCDLucid Diagnostics74.01%Insider OwnershipCompanyInsider OwnershipECORelectroCore13.80%INFUInfuSystem10.80%KRMDKORU Medical Systems18.50%LUCDLucid Diagnostics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableECORelectroCore508.30 million7.15 millionNot OptionableINFUInfuSystem41020.18 million19.10 millionOptionableKRMDKORU Medical Systems8045.93 million37.44 millionOptionableLUCDLucid Diagnostics70203.07 million189.06 millionNo DataECOR, LUCD, KRMD, and INFU HeadlinesRecent News About These CompaniesLucid Diagnostics: Positioned For A Medicare-Driven InflectionJuly 3, 2026 | seekingalpha.comLucid Diagnostics Shareholders Approve Stock Authorization IncreaseJune 24, 2026 | tipranks.comLucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks TranscriptJune 24, 2026 | seekingalpha.comLucid Diagnostics’ Earnings Call: Momentum Amid Cash StrainJune 12, 2026 | theglobeandmail.comWhy Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 ResultsJune 3, 2026 | finance.yahoo.comWhy Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 ResultsJune 2, 2026 | insidermonkey.comDennis Matheis Buys 245,000 Shares of Lucid Diagnostics (NASDAQ:LUCD) StockMay 22, 2026 | insidertrades.comCanaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD)May 16, 2026 | theglobeandmail.comLucid Diagnostics Inc (LUCD) Q1 2026 Earnings Call Highlights: Exceeding Test Targets and ...May 15, 2026 | finance.yahoo.comLucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2026 Earnings Call TranscriptMay 15, 2026 | insidermonkey.comPAVmed Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 15, 2026 | prnewswire.comLucid Diagnostics Earnings Call Balances Progress, PressureMay 14, 2026 | tipranks.comLucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comLucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue EstimatesMay 14, 2026 | zacks.comLucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 14, 2026 | prnewswire.comLucid Diagnostics Inc (LUCD) Q1 2026 Earnings Report Preview: What To Look ForMay 13, 2026 | finance.yahoo.comLucid Diagnostics Inc. (LUCD) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseMay 8, 2026 | zacks.comPAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026May 1, 2026 | prnewswire.comLucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026April 30, 2026 | prnewswire.comLucid Diagnostics closes $18M offeringApril 24, 2026 | massdevice.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026EVs Are Big Winners of the Iran War—Just Not American OnesBy Jessica Mitacek | June 24, 2026Carnival's Second Quarter: Is the Stock Still Complicated?By Peter Frank | June 25, 2026SpaceX’s Historic IPO Has Already Sparked a 2X ETF FrenzyBy Ryan Hasson | June 22, 2026Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before EarningsBy Sam Quirke | July 15, 2026ECOR, LUCD, KRMD, and INFU Company DescriptionselectroCore NASDAQ:ECOR$6.40 +0.33 (+5.44%) Closing price 04:00 PM EasternExtended Trading$6.34 -0.06 (-0.89%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.InfuSystem NYSE:INFU$9.15 +0.21 (+2.35%) Closing price 04:00 PM EasternExtended Trading$9.15 0.00 (0.00%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.KORU Medical Systems NASDAQ:KRMD$4.03 -0.03 (-0.74%) Closing price 04:00 PM EasternExtended Trading$4.22 +0.19 (+4.74%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.Lucid Diagnostics NASDAQ:LUCD$0.97 0.00 (-0.27%) Closing price 04:00 PM EasternExtended Trading$0.96 0.00 (-0.38%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
